First Patient Dosed in Phase 1 Clinical Trial of PulseSight Therapeutics’ Treatment for Dry AMD, GA Posted on July 7, 2025January 15, 2026 by edgover
PulseSight Therapeutics Reports First Patient Dosing with PST-611 in P-I (PST-611-CT1) Trial for Dry AMD/Geographic Atrophy Posted on July 7, 2025January 15, 2026 by edgover
First patient dosed in trial for novel dry AMD treatment PST-611 Posted on July 7, 2025January 15, 2026 by edgover
PulseSight launches first-in-human trial of AMD gene therapy Posted on July 7, 2025January 21, 2026 by edgover
PulseSight Therapeutics: Nonviral Gene Therapy for Dry AMD Posted on April 16, 2025January 15, 2026 by edgover
PulseSight Therapeutics SAS receives funds to support clinical trials of PST-611 Posted on February 20, 2025January 18, 2026 by edgover
PulseSight Therapeutics closes Series A financing for dry AMD phase 1 clinical study Posted on February 14, 2025January 18, 2026 by edgover
